• Explore /
  • Poster
  • / ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer.

ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer.

Abstract Poster

Authors

Nadia Harbeck

Nadia Harbeck

Breast Center, University of Munich (LMU), Munich, Germany

Nadia Harbeck , Oleg Gluz , Matthias Christgen , Monika Graeser , Felix Hilpert , Katja Krauss , Hans Heinrich Kreipe , Ulrike Nitz , Ronald E. Kates , Timo Schinkoethe , Rachel Wuerstlein , Sherko Kuemmel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

2018-003749-40

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS596)

DOI

10.1200/JCO.2019.37.15_suppl.TPS596

Abstract #

TPS596

Poster Bd #

88a

Abstract Disclosures

Similar Posters

First Author: Nadia Harbeck

First Author: Malinda T West

First Author: Jerome Fayette

First Author: Jesús Fuentes Antrás